New York, March 05, 2015 -- Moody's Investors Service placed the Baa1 senior unsecured ratings of AbbVie Inc. ("AbbVie") under review for downgrade. At the same time, Moody's affirmed AbbVie's Prime-2 commercial paper rating. These rating actions follow the announcement that AbbVie has made an offer to acquire Pharmacyclics Inc. ("Pharmacyclics") for approximately $21 billion in cash and stock.
Vollständigen Artikel bei Moodys lesen